These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 27539178)

  • 1. Cardiovascular Effects of the New Weight Loss Agents.
    Vorsanger MH; Subramanyam P; Weintraub HS; Lamm SH; Underberg JA; Gianos E; Goldberg IJ; Schwartzbard AZ
    J Am Coll Cardiol; 2016 Aug; 68(8):849-59. PubMed ID: 27539178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The risk of cardiovascular complications with current obesity drugs.
    Chao AM; Wadden TA; Berkowitz RI; Quigley K; Silvestry F
    Expert Opin Drug Saf; 2020 Sep; 19(9):1095-1104. PubMed ID: 32750250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination phentermine and topiramate extended release in the management of obesity.
    Alfaris N; Minnick AM; Hopkins CM; Berkowitz RI; Wadden TA
    Expert Opin Pharmacother; 2015 Jun; 16(8):1263-74. PubMed ID: 25958964
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modern obesity pharmacotherapy: weighing cardiovascular risk and benefit.
    Cunningham JW; Wiviott SD
    Clin Cardiol; 2014 Nov; 37(11):693-9. PubMed ID: 25223901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gender-related issues in the pharmacology of new anti-obesity drugs.
    Cataldi M; Muscogiuri G; Savastano S; Barrea L; Guida B; Taglialatela M; Colao A
    Obes Rev; 2019 Mar; 20(3):375-384. PubMed ID: 30589980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug safety evaluation of naltrexone/bupropion for the treatment of obesity.
    Verpeut JL; Bello NT
    Expert Opin Drug Saf; 2014 Jun; 13(6):831-41. PubMed ID: 24766397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New medications for treatment of obesity: metabolic and cardiovascular effects.
    Pucci A; Finer N
    Can J Cardiol; 2015 Feb; 31(2):142-52. PubMed ID: 25661549
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Answers to Clinical Questions in the Primary Care Management of People with Obesity: Pharmacologic Management.
    Fujioka K; Braverman-Panza J
    J Fam Pract; 2016 Jul; 65(7 Suppl):S16-23. PubMed ID: 27565106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is cardiometabolic risk improved by weight-loss drugs?
    Astrup A
    Lancet; 2010 Aug; 376(9741):567-8. PubMed ID: 20673996
    [No Abstract]   [Full Text] [Related]  

  • 10. Obesity: new perspectives and pharmacotherapies.
    Palamara KL; Mogul HR; Peterson SJ; Frishman WH
    Cardiol Rev; 2006; 14(5):238-58. PubMed ID: 16924165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacotherapy for weight loss: the cardiovascular effects of the old and new agents.
    Walter CP; Bleske BE; Dorsch MP
    J Clin Pharm Ther; 2014 Oct; 39(5):475-84. PubMed ID: 24924286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The pharmacotherapy of obesity].
    Budai KA; Mirzahosseini A; Noszál Béla ; Tóth G
    Acta Pharm Hung; 2015; 85(1):3-17. PubMed ID: 26137782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current and emerging pharmacotherapies for obesity in Australia.
    Hocking S; Dear A; Cowley MA
    Obes Res Clin Pract; 2017; 11(5):501-521. PubMed ID: 28818558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacologic therapy of obesity: mechanisms of action and cardiometabolic effects.
    Montan PD; Sourlas A; Olivero J; Silverio D; Guzman E; Kosmas CE
    Ann Transl Med; 2019 Aug; 7(16):393. PubMed ID: 31555707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug treatment of obesity: current status and future prospects.
    Kakkar AK; Dahiya N
    Eur J Intern Med; 2015 Mar; 26(2):89-94. PubMed ID: 25634851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-obesity therapy for cardiovascular disease prevention: potential expected roles of glucagon-like peptide-1 receptor agonists.
    Sawami K; Tanaka A; Node K
    Cardiovasc Diabetol; 2022 Sep; 21(1):176. PubMed ID: 36068534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors: A Randomized Clinical Trial.
    Nissen SE; Wolski KE; Prcela L; Wadden T; Buse JB; Bakris G; Perez A; Smith SR
    JAMA; 2016 Mar; 315(10):990-1004. PubMed ID: 26954408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging pharmacotherapy for treating obesity and associated cardiometabolic risk.
    Caterson ID; Finer N
    Asia Pac J Clin Nutr; 2006; 15 Suppl():55-62. PubMed ID: 16928662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug treatment of obesity in cardiovascular disease.
    Charakida M; Finer N
    Am J Cardiovasc Drugs; 2012 Apr; 12(2):93-104. PubMed ID: 22292446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-obesity drugs.
    Rankin W; Wittert G
    Curr Opin Lipidol; 2015 Dec; 26(6):536-43. PubMed ID: 26382553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.